Hangzhou Haobo Pharmaceutical

Haobo Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative nucleic acid drugs, with a primary focus on achieving a functional cure for chronic Hepatitis B. The company utilizes its proprietary Med-SIRS platform to design and develop small interfering RNA (siRNA) therapeutics with enhanced potency and stability. Its lead candidate, AHB-137, is a liver-targeted siRNA that has demonstrated promising results in reducing HBsAg levels in clinical trials. Headquartered in Hangzhou, China, Haobo Pharma is backed by prominent venture capital firms and is expanding its pipeline to address other viral and metabolic diseases. The company's leadership team brings extensive experience from global pharmaceutical companies, driving its mission to provide transformative treatments for patients worldwide.